½ÃÀ庸°í¼­
»óǰÄÚµå
1672781

¹ÙÀÌ¿ÀÀǾàǰ ¹× ¹ÙÀÌ¿À¸Þµð½Å ½ÃÀå : Á¦Ç° À¯Çüº°, ¿ëµµº°, À¯Çüº°, Åõ¿© °æ·Îº°, ȯÀÚ ¼Ó¼ºº°, Áö¿ªº°

Biopharmaceutical and Biomedicine Market, By Product Type, By Application, By Type, By Route of Administration, By Patient Demographics, By Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Coherent Market Insights | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ¹ÙÀÌ¿ÀÀǾàǰ ¹× ¹ÙÀÌ¿À¸Þµð½Å ½ÃÀåÀº 2025³â¿¡´Â 6,402¾ï 6,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2032³â¿¡´Â 1Á¶ 4,251¾ï 7,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2025-2032³â¿¡ CAGR 12.1%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸®Æ÷Æ® ¹üÀ§ ¸®Æ÷Æ® »ó¼¼
±âÁØ¿¬µµ 2024 2025³â ½ÃÀå ±Ô¸ð 6,402¾ï 6,000¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2020-2024³â ¿¹Ãø ±â°£ 2025-2032³â
¿¹Ãø ±â°£ : 2025-2032³â CAGR : 12.10% 2032³â °¡Ä¡ ¿¹Ãø 1Á¶ 4,251¾ï 7,000¸¸ ´Þ·¯
µµÇ¥. ¹ÙÀÌ¿ÀÀǾàǰ ¹× ¹ÙÀÌ¿À¸Þµð½Å ½ÃÀåÀÇ Áö¿ªº° Á¡À¯À²(%), 2025³â
Biopharmaceutical and Biomedicine Market-IMG1

¼¼°è ¹ÙÀÌ¿ÀÀǾàǰ ¹× ¹ÙÀÌ¿ÀÀǾàǰ ½ÃÀåÀº Áö³­ ¼ö½Ê³â°£ °ý¸ñÇÒ ¸¸ÇÑ ¼ºÀåÀ» °ÅµìÇØ ¿Ô½À´Ï´Ù. °ø°ø ¹× ¹Î°£ ºÎ¹®ÀÇ R&D ÅõÀÚ Áõ°¡´Â »ý¹°Á¦Á¦, À¯Àü°øÇÐ, ½Å¾à °³¹ß ºÐ¾ß¿¡¼­ ȹ±âÀûÀÎ ±â¼ú Çõ½ÅÀ¸·Î À̾îÁö°í ÀÖ½À´Ï´Ù. ¼¼Æ÷ ¹× À¯ÀüÀÚ Ä¡·á, Àç»ýÀÇ·á, ´ÜŬ·Ð Ç×ü, °³ÀθÂÃãÇü ÀÇ·á¿Í °°Àº ºÐ¾ßÀÇ ¹ßÀüÀº ¸¸¼ºÁúȯ°ú »ý¸íÀ» À§ÇùÇÏ´Â Áúº´À» Ä¡·áÇÒ ¼ö ÀÖ´Â À¯¸ÁÇÑ Àü¸ÁÀ» Á¦½ÃÇϰí ÀÖ½À´Ï´Ù. Àα¸ÀÇ ±Þ¼ÓÇÑ °í·ÉÈ­¿Í ¾Ï, ´ç´¢º´, ½Å°æÁúȯÀÇ Àü ¼¼°è ¹ßº´·ü Áõ°¡´Â º¸´Ù È¿°úÀûÀÎ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÇÕ¼º»ý¹°Çаú À¯Àü°øÇÐÀÌ Å©°Ô ¹ßÀüÇÔ¿¡ µû¶ó °úÇÐÀÚµéÀº ¹é½Å, È£¸£¸ó, Ç÷¾× ¼ººÐ°ú °°Àº ÷´Ü »ý¹°Á¦Á¦¸¦ ¼³°èÇÏ°í °³¹ßÇÒ ¼ö ÀÖ°Ô µÇ¾ú°í, ÀÌ´Â ÇコÄÉ¾î ¹× ±âŸ »ê¾÷ ºÐ¾ß¿¡¼­ Áß¿äÇÑ ÀÀ¿ëÀ» ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¼ºÀå ±âȸ´Â ¿©ÀüÈ÷ Å©Áö¸¸, ³ôÀº R&D ºñ¿ë°ú ¾ö°ÝÇÑ ±ÔÁ¦´Â ¿©ÀüÈ÷ °úÁ¦·Î ³²¾Æ ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ:

¼¼°è ¹ÙÀÌ¿ÀÀǾàǰ ¹× ¹ÙÀÌ¿ÀÀǾàǰ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀ¸·Î´Â ¸¸¼ºÁúȯ ¹× »ýȰ½À°üº´ÀÇ À¯º´·ü Áõ°¡, ´Ù¾çÇÑ °Ç°­¹®Á¦¿¡ Ãë¾àÇÑ ³ë·ÉÀα¸ÀÇ ±ÞÁõ, ¿ì¼öÇÑ ÇコÄɾî Á¦Ç° ¹× ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ Ã·´Ü ´Ü¹éÁú ¿£Áö´Ï¾î¸µ, ÀçÁ¶ÇÕ DNA ±â¼ú, Áٱ⼼Æ÷ ¿¬±¸¿¡ ´ëÇÑ °ø°ø ¹× ¹Î°£ ±â¾÷ÀÇ ¸·´ëÇÑ ÅõÀÚ·Î ÀÎÇØ »õ·Î¿î »ý¹°ÇÐÀû ¾à¹° ¹× Ä¡·á¹ý °³¹ßÀÌ °¡´ÉÇØÁ³½À´Ï´Ù. ±×·¯³ª ÀÓ»ó½ÃÇè¿¡¼­ ½ÂÀο¡ À̸£´Â ÀǾàǰ °³¹ß °ü·Ã ºñ¿ëÀÌ ¸Å¿ì ³ô°í, ¼¶¼¼ÇÑ Á¦Á¶ °øÁ¤°ú ¾ö°ÝÇÑ ±ÔÁ¦ °¨µ¶À¸·Î ÀÎÇØ ½ÃÀåÀÇ ±Þ¼ÓÇÑ È®ÀåÀº ¿©ÀüÈ÷ ¾ïÁ¦µÇ°í ÀÖ½À´Ï´Ù. µ¿½Ã¿¡ ¸ÂÃãÇü ÀÇ·á¿Í Á¶Á÷ ¹× Àå±â 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ½ÃÀå ¹ßÀüÀÇ »õ·Î¿î ±æÀ» Á¦½ÃÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¿¬±¸ ±â°ü°ú ¾÷°è ±â¾÷ÀÇ ÆÄÆ®³Ê½ÊÀº À¯¸ÁÇÑ ½Å¾à Èĺ¸¹°ÁúÀÇ »ó¿ëÈ­¸¦ °¡¼ÓÈ­ÇÏ°í »ý»ê ºñ¿ëÀ» ³·Ãß´Â µ¥ µµ¿òÀÌ µÇ°í ÀÖ½À´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

¼¼°èÀÇ ¹ÙÀÌ¿ÀÀǾàǰ ¹× ¹ÙÀÌ¿ÀÀǾàǰ ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®ÇÏ¿© 2024³âÀ» ±âÁØ ¿¬µµ·Î ÇÏ¿© ¿¹Ãø ±â°£(2025-2032³â) ½ÃÀå ±Ô¸ð(10¾ï ´Þ·¯)¿Í ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» Á¶»ç ºÐ¼®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

¶ÇÇÑ ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀû ¸ÅÃâ ±âȸ¸¦ ¹àÈ÷°í, ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.

¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÇ °æÀï Àü·« µî¿¡ ´ëÇÑ Áß¿äÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù.

¼¼°è ¹ÙÀÌ¿ÀÀǾàǰ ¹× ¹ÙÀÌ¿À¸Þµð½Å ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À» ±â¾÷ ¼Ò°³, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä Æ¯Â¡, À繫 ¼º°ú, Àü·« µîÀÇ ¸Å°³º¯¼ö¸¦ ±â¹ÝÀ¸·Î ÇÁ·ÎÆÄÀϸµÇÕ´Ï´Ù.

ÁÖ¿ä ±â¾÷¿¡´Â Novartis AG, Johnson &Johnson, Pfizer, Inc., Sanofi S.A., Eli Lilly and Company, Hoffmann-La Roche AG, AbbVie Inc., Bristol-Myers Squibb, Qiagen N.V., Affimed N.V., Celgene Corporation, Amgen Inc., Merck &Co, Inc., GSK Plc, Regeneron Pharmaceuticals µîÀÌ Æ÷ÇԵ˴ϴÙ.

ÀÌ º¸°í¼­ÀÇ ÀλçÀÌÆ®¸¦ ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯ÇüÈ­, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü·«¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô ½ÃÀå ÁøÃâ±â¾÷, À繫 ºÐ¼®°¡ µî ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀº ¼¼°è ¹ÙÀÌ¿ÀÀǾàǰ ¹× ¹ÙÀÌ¿ÀÀǾàǰ ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ½±°Ô ³»¸± ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»çÀÇ ¸ñÀû°ú ÀüÁ¦Á¶°Ç

  • Á¶»ç ¸ñÀû
  • ÀüÁ¦Á¶°Ç
  • ¾à¾î

Á¦2Àå ½ÃÀå Àü¸Á

  • ¸®Æ÷Æ® ¼³¸í
    • ½ÃÀåÀÇ Á¤ÀÇ¿Í ¹üÀ§
  • °³¿ä

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

  • ½ÃÀå ¿ªÇÐ
  • µå¶óÀ̹ö
  • ¾ïÁ¦¿äÀÎ
  • ±âȸ
  • ¿µÇ⠺м®
  • ÁÖ¿ä ¹ßÀü
  • ±ÔÁ¦ ½Ã³ª¸®¿À
  • Á¦Ç° ¹ß¸Å/½ÂÀÎ
  • PEST ºÐ¼®
  • PORTERÀÇ »ê¾÷ ºÐ¼®
  • ÇÕº´°ú Àμö ½Ã³ª¸®¿À
  • ¾÷°è µ¿Çâ

Á¦4Àå ¼¼°èÀÇ ¹ÙÀÌ¿ÀÀǾàǰ ¹× ¹ÙÀÌ¿À¸Þµð½Å ½ÃÀå, Á¦Ç° À¯Çüº°, 2020-2032³â, (10¾ï ´Þ·¯)

  • ¹ÙÀÌ¿ÀÀǾàǰ
  • ³ª³ë ÀÇ·á
  • ¼¼Æ÷¡¤À¯ÀüÀÚ Ä¡·á
  • ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º
  • ºÐÀÚ È¿¼Ò¿Í ŰƮ

Á¦5Àå ¼¼°èÀÇ ¹ÙÀÌ¿ÀÀǾàǰ ¹× ¹ÙÀÌ¿À¸Þµð½Å ½ÃÀå, ¿ëµµº°, 2020-2032³â, (10¾ï ´Þ·¯)

  • Ä¡·á
  • Áø´Ü
  • ¿¬±¸°³¹ß

Á¦6Àå ¼¼°èÀÇ ¹ÙÀÌ¿ÀÀǾàǰ ¹× ¹ÙÀÌ¿À¸Þµð½Å ½ÃÀå, À¯Çüº°, 2020-2032³â, (10¾ï ´Þ·¯)

  • ºê·£µå ¹ÙÀÌ¿ÀÀǾàǰ
  • Á¦³×¸¯ ¹ÙÀÌ¿ÀÀǾàǰ

Á¦7Àå ¼¼°èÀÇ ¹ÙÀÌ¿ÀÀǾàǰ ¹× ¹ÙÀÌ¿À¸Þµð½Å ½ÃÀå, Åõ¿© °æ·Îº°, 2020-2032³â, (10¾ï ´Þ·¯)

  • °æ±¸
  • Á¤¸Æ³»
  • ÇÇÇÏ
  • ±ÙÀ°³»

Á¦8Àå ¼¼°èÀÇ ¹ÙÀÌ¿ÀÀǾàǰ ¹× ¹ÙÀÌ¿À¸Þµð½Å ½ÃÀå, ȯÀÚ Àα¸ µ¿Åº°, 2020-2032³â, (10¾ï ´Þ·¯)

  • ¼ºÀÎ
  • ¼Ò¾Æ
  • °í·ÉÀÚ

Á¦9Àå ¼¼°èÀÇ ¹ÙÀÌ¿ÀÀǾàǰ ¹× ¹ÙÀÌ¿À¸Þµð½Å ½ÃÀå, Áö¿ªº°, 2020-2032³â, °¡Ä¡(10¾ï ´Þ·¯)

  • ºÏ¹Ì
  • ¶óƾ¾Æ¸Þ¸®Ä«
  • À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áßµ¿
  • ¾ÆÇÁ¸®Ä«

Á¦10Àå °æÀï ±¸µµ

  • Novartis AG
  • Johnson & Johnson
  • Pfizer, Inc.
  • Sanofi S.A.
  • Eli Lilly and Company
  • F.Hoffmann-La Roche AG
  • AbbVie Inc.
  • Bristol-Myers Squibb
  • Qiagen N.V.
  • Affimed N.V.
  • Celgene Corporation
  • Amgen Inc.
  • Merck & Co., Inc.
  • GSK Plc
  • Regeneron Pharmaceuticals

Á¦11Àå ¾Ö³Î¸®½ºÆ®ÀÇ ±ÇÀå»çÇ×

Á¦12Àå Âü°í ¹®Çå°ú Á¶»ç ¹æ¹ý

  • Âü°í ¹®Çå
  • Á¶»ç ¹æ¹ý
  • ÃâÆÇ»ç ¼Ò°³
KSA 25.04.14

Global Biopharmaceutical and Biomedicine Market is estimated to be valued at USD 640.26 Bn in 2025 and is expected to reach USD 1,425.17 Bn by 2032, growing at a compound annual growth rate (CAGR) of 12.1% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 640.26 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 12.10% 2032 Value Projection: USD 1,425.17 Bn
Figure. Biopharmaceutical And Biomedicine Market Share (%), By Region 2025
Biopharmaceutical and Biomedicine Market - IMG1

The global biopharmaceutical and biomedicine market has witnessed tremendous growth over the past few decades. Rising investment in research and development activities by both public and private sectors has led to path breaking innovations in the field of biologics, genetic engineering and novel drug development. Advancements in areas such as cell and gene therapy, regenerative medicine, monoclonal antibodies and personalized medicine holds promising prospects for the treatment of chronic and life-threatening diseases. Rapidly aging population and growing incidence of cancer, diabetes and neurological disorders globally has spurred demand for more effective therapeutic options. Moreover, substantial progress in synthetic biology and genetic engineering is allowing scientists to design and develop advanced biologics like vaccines, hormones and blood components, with significant applications in healthcare and other industrial verticals. While growth opportunities remain vast, high R&D costs and stringent regulatory framework continue posing challenges.

Market Dynamics:

The key factors driving the growth of global biopharmaceutical and biomedicine market include rising prevalence of chronic and lifestyle diseases, rapid increase in geriatric population susceptible to various health issues, growing demand for superior healthcare products and services. Moreover, heavy investments by both public and private players in advanced protein engineering, recombinant DNA technology and stem cell research have enabled development of novel biologic drugs and therapies. However, extremely high costs associated with drug development from clinical trial to approval, coupled with delicate manufacturing processes and stringent regulatory oversight continue to restrain faster market expansion. At the same time, growing focus on personalized medicine and 3D bioprinting of tissues and organ present new avenues for market progress. In addition, partnerships between research institutes and industry players are helping accelerate commercialization of promising drug candidates and lower production costs.

Key Features of the Study:

This report provides in-depth analysis of the global biopharmaceutical and biomedicine market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global biopharmaceutical and biomedicine market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Novartis AG, Johnson & Johnson, Pfizer, Inc., Sanofi S.A., Eli Lilly and Company, Hoffmann-La Roche AG, AbbVie Inc., Bristol-Myers Squibb, Qiagen N.V., Affimed N.V., Celgene Corporation, Amgen Inc., Merck & Co., Inc., GSK Plc, and Regeneron Pharmaceuticals

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global biopharmaceutical and biomedicine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global biopharmaceutical and biomedicine market

Market Segmentation

  • Product Type Insights (Revenue, USD Bn, 2020 - 2032)
    • Biopharmaceuticals
    • Monoclonal Antibodies
    • Vaccines
    • Recombinant Human Insulin
    • Human Growth Hormone
    • Erythropoietin
    • Interferon
    • Colony Stimulating Factor
    • Blood Factors
    • Fusion Protein
    • Others
    • Nanomedicine
    • Cell & Gene Therapy
    • Bioinformatics
    • Molecular Enzymes & Kits
  • Application Insights (Revenue, USD Bn, 2020 - 2032)
    • Therapeutics
    • Oncology
    • Cardiovascular Diseases
    • Neurological Disorders
    • Infectious Diseases
    • Immune Disorders
    • Diagnostics
    • In Vitro Diagnostics
    • In Vivo Diagnostics
    • Point-of-Care Testing
    • Research and Development
    • Preclinical Research
    • Clinical Trials
    • Biotechnology Research
    • Regulatory Research
  • Type Insights (Revenue, USD Bn, 2020 - 2032)
    • Branded Biopharmaceuticals
    • Generic Biopharmaceuticals
  • Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
    • Oral
    • Intravenous
    • Subcutaneous
    • Intramuscular
  • Patient Demographics Insights (Revenue, USD Bn, 2020 - 2032)
    • Adult
    • Pediatric
    • Geriatric
  • Regional Insights (Revenue, USD Bn, 2020 - 2032)
    • North America
    • U.S.
    • Canada
    • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
    • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
    • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
    • Africa
    • South Africa
    • North Africa
    • Central Africa
  • Key Players Insights
    • Novartis AG
    • Johnson & Johnson
    • Pfizer, Inc.
    • Sanofi S.A.
    • Eli Lilly and Company
    • Hoffmann-La Roche AG
    • AbbVie Inc.
    • Bristol-Myers Squibb
    • Qiagen N.V.
    • Affimed N.V.
    • Celgene Corporation
    • Amgen Inc.
    • Merck & Co., Inc.
    • GSK Plc
    • Regeneron Pharmaceuticals

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Global Biopharmaceutical and Biomedicine Market, By Product Type
    • Global Biopharmaceutical and Biomedicine Market, By Application
    • Global Biopharmaceutical and Biomedicine Market, By Type
    • Global Biopharmaceutical and Biomedicine Market, By Route of Administration
    • Global Biopharmaceutical and Biomedicine Market, By Patient Demographics
    • Global Biopharmaceutical and Biomedicine Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
  • Driver
  • Restraint
  • Opportunity
  • Impact Analysis
  • Key Developments
  • Regulatory Scenario
  • Product Launches/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario
  • Industry Trends

4. Global Biopharmaceutical and Biomedicine Market, By Product Type, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Biopharmaceuticals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Monoclonal Antibodies
    • Vaccines
    • Recombinant Human Insulin
    • Human Growth Hormone
    • Erythropoietin
    • Interferon
    • Colony Stimulating Factor
    • Blood Factors
    • Fusion Protein
    • Others
  • Nanomedicine
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Cell & Gene Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Bioinformatics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Molecular Enzymes & Kits
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Biopharmaceutical and Biomedicine Market, By Application, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Therapeutics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Oncology
    • Cardiovascular Diseases
    • Neurological Disorders
    • Infectious Diseases
    • Immune Disorders
  • Diagnostics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • In Vitro Diagnostics
    • In Vivo Diagnostics
    • Point-of-Care Testing
  • Research and Development
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Preclinical Research
    • Clinical Trials
    • Biotechnology Research
    • Regulatory Research

6. Global Biopharmaceutical and Biomedicine Market, By Type, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Branded Biopharmaceuticals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Generic Biopharmaceuticals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Biopharmaceutical and Biomedicine Market, By Route of Administration, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Intravenous
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Subcutaneous
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Intramuscular
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Biopharmaceutical and Biomedicine Market, By Patient Demographics, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Adult
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Pediatric
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Geriatric
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Biopharmaceutical and Biomedicine Market, By Region, 2020 - 2032, Value (USD Bn)

  • Introduction
    • Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
    • Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Patient Demographics, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa

10. Competitive Landscape

  • Novartis AG
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Johnson & Johnson
  • Pfizer, Inc.
  • Sanofi S.A.
  • Eli Lilly and Company
  • F.Hoffmann-La Roche AG
  • AbbVie Inc.
  • Bristol-Myers Squibb
  • Qiagen N.V.
  • Affimed N.V.
  • Celgene Corporation
  • Amgen Inc.
  • Merck & Co., Inc.
  • GSK Plc
  • Regeneron Pharmaceuticals

11. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

12. References and Research Methodology

  • References
  • Research Methodology
  • About us
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦